Compare MBUU & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBUU | TECX |
|---|---|---|
| Founded | 1982 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.4M | 618.9M |
| IPO Year | 2013 | 2018 |
| Metric | MBUU | TECX |
|---|---|---|
| Price | $24.03 | $26.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $32.20 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 239.9K | 179.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.70 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $914,590,000.00 | N/A |
| Revenue This Year | $2.14 | N/A |
| Revenue Next Year | $12.78 | N/A |
| P/E Ratio | $262.56 | ★ N/A |
| Revenue Growth | ★ 13.25 | N/A |
| 52 Week Low | $22.82 | $14.39 |
| 52 Week High | $34.97 | $39.53 |
| Indicator | MBUU | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 34.65 | 34.97 |
| Support Level | N/A | $17.83 |
| Resistance Level | $29.93 | $31.39 |
| Average True Range (ATR) | 0.99 | 1.55 |
| MACD | -0.24 | -0.45 |
| Stochastic Oscillator | 12.92 | 5.15 |
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high-end offshore and outboard motorboats, in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Most recently, in 2026, it tied up with Saxdor Yachts, focused on adventure dayboats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.